Status:
COMPLETED
Study of Oral Fampridine-SR in Multiple Sclerosis
Lead Sponsor:
Acorda Therapeutics
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
To assess the safety and efficacy of 10 milligram (mg) twice a day (b.i.d.) Fampridine-SR in patients diagnosed with multiple sclerosis (MS), in a double-blind, placebo-controlled, parallel group stud...
Detailed Description
Multiple sclerosis (MS) is a disorder of the body's immune system that affects the central nervous system (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing com...
Eligibility Criteria
Inclusion
- Have a confirmed diagnosis of multiple sclerosis
- Are able to walk with or without an assistive device
Exclusion
- Pregnancy, breastfeeding or females of childbearing potential not using adequate birth control
- Participating in other investigational drug trials
- A medical history or clinical findings that preclude entry into the study
- A medication history that precludes entry into the study
- Previously treated with 4-aminopyridine (4-AP)
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00127530
Start Date
May 1 2005
End Date
September 1 2006
Last Update
September 11 2018
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama
Birmingham, Alabama, United States, 35233
2
Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States, 85013
3
USC, Keck School of Medicine
Los Angeles, California, United States, 90033
4
UC Davis
Sacramento, California, United States, 95817